Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy plus nimotuzumab and vinorelbine versus multiple elective radiotherapy courses with nimotuzumab and vinorelbine for newly diagnosed pediatric DIPG
2015-002185-23Phase 3Active
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Nov 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nimotuzumab and vinorelbine in diffuse intrinsic pontine glioma (DIPG) and brainstem glioma (2 arms), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Best response up to week 36. Started Nov 2020; status: active.
02
Drugs
nimotuzumabvinorelbine
03
Conditions
diffuse intrinsic pontine glioma (DIPG)brainstem glioma
Beyond the preview
Go deeper on 2015-002185-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002185-23.